(Q34512370)

2 August 2017

title

Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial (English)

1 reference

2 August 2017

0 references

1 reference

S H Hohnloser

1

1 reference

2 August 2017

K H Kuck

series ordinal

2

1 reference

2 August 2017

J Lilienthal

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

2 August 2017

1 reference

2 August 2017

volume

356

1 reference

2 August 2017

issue

9244

1 reference

2 August 2017

page(s)

1789-1794

1 reference

Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors, and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Atrial fibrillation: maintenance of sinus rhythm versus rate control

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Effect of radiofrequency catheter ablation on health-related quality of life and activities of daily living in patients with recurrent arrhythmias.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Quality of life in patients with supraventricular arrhythmia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Comparisons of quality of life and cardiac performance after complete atrioventricular junction ablation and atrioventricular junction modification in patients with medically refractory atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest : the Cardiac Arrest Study Hamburg (CASH)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

The effect of cardioversion on maximal exercise capacity in patients with chronic atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

Functional capacity before and after cardioversion of atrial fibrillation: a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

The case for inpatient initiation of antiarrhythmic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2903230-X

7 January 2021

10.1016/S0140-6736(00)03230-X

Identifiers

DOI

1 reference

2 August 2017

1 reference